Clinical Significance of Recent Lipid Trials on Reducing Risk in Patients with Type 2 Diabetes Mellitus

American Journal of Cardiology

Volumn 99, Issue 4 SUPPL., 2007, Pages 133-140

  Jones, Peter H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TARGETING; DYSLIPIDEMIA; GLUCOSE TOLERANCE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; MONOTHERAPY; MORBIDITY; MORTALITY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PRACTICE GUIDELINES; RISK FACTORS;

EID: 33846932118     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.11.014     Document Type: Article

References (38)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
3. Haffner S. Rationale for new American Diabetes Association Guidelines: are national cholesterol education program goals adequate for the patient with diabetes mellitus?. Am J Cardiol 96 (2005) 33E-36E
4. Haffner S.M. Dyslipidemia management in adults with diabetes. Diabetes Care 27 suppl (2004) S68-S71
5. Turner R.C., Millns H., Neil H.A., Stratton I.M., Manley S.E., Matthews D.R., and Holman R.R. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316 (1998) 823-828
6. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005 (2005), US Dept of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA
7. Nesto R.W. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 5 (2005) 379-387
8. Bhatt D.L., Steg P.G., Ohman E.M., Hirsch A.T., Ikeda Y., Mas J.L., Goto S., Liau C.S., Richard A.J., Rother J., and Wilson P.W. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295 (2006) 180-189
9. Collins R., Armitage J., Parish S., Sleigh P., and Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
10. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
11. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
12. Ansquer J.C., Foucher C., Rattier S., Taskinen M.R., and Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45 (2005) 485-493
13. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 24 (2004) e149-e161
14. Snow V., Aronson M.D., Hornbake E.R., Mottur-Pilson C., and Weiss K.B. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 140 (2004) 644-649
15. Vijan S., and Hayward R.A. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 140 (2004) 650-658
16. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., and Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
17. Costa J., Borges M., David C., and Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332 (2006) 1115-1124
18. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
19. Pedersen T.R., Faergeman O., Kastelein J.J., Olsson A.G., Tikkanen M.J., Holme I., Larsen M.L., Bendiksen F.S., Lindahl C., Szarek M., and Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
20. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., and Fuller J.H. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
21. Pyörälä K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., and Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (1997) 614-620
22. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E., and Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
23. Goldberg R.B., Mellies M.J., Sacks F.M., Moye L.A., Howard B.V., Howard W.J., Davis B.R., Cole T.G., Pfeffer M.A., Braunwald E., and CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 98 (1998) 2513-2519
24. Sever P.S., Poulter N.R., Dahlof B., Wedel H., Collins R., Beevers G., Caulfield M., Kjeldsen S.E., Kristinsson A., McInnes G.T., et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 28 (2005) 1151-1157
25. Shepherd J., Barter P., Carmena R., Deedwania P., Fruchart J.C., Haffner S., Hsia J., Breazna A., LaRosa J., Grundy S., and Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29 (2006) 1220-1226
26. Corti R., Osende J., Hutter R., Viles-Gonzalez J.F., Zafar U., Valdivieso C., Mizsei G., Fallon J.T., Fuster V., and Badimon J.J. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. Atherosclerosis 190 (2007) 106-113
27. Chinetti-Gbaguidi G., Fruchart J.C., and Staels B. Pleiotropic effects of fibrates. Curr Atheroscler Rep 7 (2005) 396-401
28. Okopien B., Krysiak R., and Herman Z.S. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 91 (2006) 1770-1778
29. Birjmohun R.S., Hutten B.A., Kastelein J.J., and Stroes E.S. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 45 (2005) 185-197
30. Tenenbaum A., Motro M., Fisman E.Z., Schwammenthal E., Adler Y., Goldenberg I., Leor J., Boyko V., Mandelzweig L., and Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109 (2004) 2197-2202
31. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
32. Grundy S.M., Vega G.L., Yuan Z., Battisti W.P., Brady W.E., and Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 95 (2005) 462-468
33. Derosa G., Cicero A.E., Bertone G., Piccinni M.N., Ciccarelli L., and Roggeri D.E. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther 26 (2004) 1599-1607
34. Athyros V.G., Papageorgiou A.A., Athyrou V.V., Demitriadis D.S., and Kontopoulos A.G. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 25 (2002) 1198-1202
35. Muhlestein J.B., May H.T., Jensen J.R., Horne B.D., Lanman R.B., Lavasani F., Wolfert R.L., Pearson R.R., Yannicelli H.D., and Anderson J.L. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 48 (2006) 396-401
36. Robins S.J., Collins D., Wittes J.T., Papademetriou V., Deedwania P.C., Schaefer E.J., McNamara J.R., Kashyap M.L., Hershman J.M., Wexler L.F., Rubins H.B., and VA-HIT Study Group. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
37. Goldenberg I., Goldbourt U., Boyko V., Behar S., Reicher-Reiss S., and BIP Study Group. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am J Cardiol 97 (2006) 466-471
38. Patient information guide. Action to Control Cardiovascular Risk in Diabetes (ACCORD). [ACCORD trial website.] Available at: http://www.accordtrial.org. Accessed July 25, 2006.